[Pharmron: Net profit in the first three quarters increased by 9.31% year-on-year] On October 27, Pharmaron (300759.SZ) announced that its revenue in the third quarter was 4.408 billion yuan, a year-on-year increase of 20.94%; net profit was 497 million yuan, a year-on-year increase of 13.06%. Revenue in the first three quarters was 12.003 billion yuan, a year-on-year increase of 19.01%; net profit was 1.247 billion yuan, a year-on-year increase of 9.31%. In the first three quarters, the revenue of the company's laboratories and factories located in China that serve global customers increased by 22.15% year-on-year, accounting for 89.84% of the company's operating revenue; the revenue of the company's laboratories and factories located overseas fell by 3.00% year-on-year, accounting for 10.16% of the company's operating revenue. The company's new orders increased by more than 30% year-on-year. Among them, new orders signed by the laboratory services sector increased by more than 25% year-on-year, new orders signed by the CDMO service sector increased by more than 40% year-on-year, and new orders signed by the clinical research services sector increased by more than 25% year-on-year. Xiaocai Note: The company’s Q3 net profit was 497 million, and Q2 net profit was 415 million. Based on this calculation, Q3 net profit increased by 19% month-on-month.